Rocket Pharmaceuticals, Inc. (RCKT)

21.53 +0.10 (+0.47%) 收市：04:00PM EDT

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Cranbury, NJ 08512
United States
609 659 8001
https://www.rocketpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 268

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Gaurav D. Shah M.D.	CEO & Director	1.01M	無	1975
Ms. Kinnari Patel M.B.A., Pharm.D.	Head of R&D, President & COO	846.11k	無	1979
Mr. Mayo Pujols	Chief Technical Officer	877.69k	無	1969
Mr. Jonathan Schwartz M.D.	Chief Medical & Gene Therapy Officer	657.87k	627.82k	1964
Mr. Aaron Ondrey	Chief Financial Officer	無	無	1977
Mr. Martin Louis Wilson J.D.	General Counsel, Chief Compliance Officer & Chief Corporate Officer	149.95k	無	1976
Kevin Giordano	Director of Corporate Communications	無	無	無
Ms. Isabel Carmona J.D.	Chief People Officer	無	無	無
Dr. Gayatri R. Rao J.D., M.D.	Senior VP of Clinical Safety & Chief Regulatory Officer	無	無	無
Mr. Raj Prabhakar M.B.A.	Chief Business Officer	619.13k	無	1974

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

公司管治

截至 2024年6月1日 止，Rocket Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：4；董事會：9；股東權利：6；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。